Data / Research funding / Arizona / Nuvox Pharma, LLC
Nuvox Pharma, LLC: 4 NIH awards ($3.8M), fiscal years 2021 to 2026
Nuvox Pharma, LLC in Tucson, AZ is funded under 4 NIH awards ($3.8M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- WHNYG96UDLJ8
- State
- Arizona
Awards
4 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma | NIH | National Cancer Institute | 2022 to 2023 | $1,492,571 | May 24, 2010 | February 29, 2024 | UNGER, EVAN CHARLES | reporter.nih.gov |
| Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic | NIH | National Cancer Institute | 2025 | $919,366 | September 22, 2025 | August 31, 2027 | UNGER, EVAN CHARLES | reporter.nih.gov |
| Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $900,552 | April 15, 2023 | March 31, 2026 | UNGER, EVAN CHARLES | reporter.nih.gov |
| NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $478,050 | September 15, 2021 | August 31, 2024 | UNGER, EVAN CHARLES | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 2 | $1,219,309 | 0 | $0 |
| 2024 | 1 | $299,243 | 0 | $0 |
| 2023 | 2 | $793,937 | 0 | $0 |
| 2022 | 1 | $1,000,000 | 0 | $0 |
| 2021 | 1 | $478,050 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed) | PAR-27-089 | NIH | 93.394 | November 2, 2026 | Not listed | Same assistance listing 93.394 as 2 awards here |
| Functional Target Validation for Alzheimer's Disease-Related Dementias | RFA-NS-26-034 | NIH | 93.853 | November 6, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required) | PAR-27-007 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | RFA-CA-27-001 | NIH | 93.394 | November 10, 2026 | $150,000 | Same assistance listing 93.394 as 2 awards here |
| Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-27-002 | NIH | 93.394 | November 10, 2026 | $300,000 | Same assistance listing 93.394 as 2 awards here |
| Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) | RFA-NS-26-001 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) | RFA-NS-26-030 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.853 | November 18, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.853 | November 18, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) | PAR-25-052 | NIH | 93.853 | November 19, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.394 | November 20, 2026 | Not listed | Same assistance listing 93.394 as 2 awards here |
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | RFA-AT-25-003 | NIH | 93.853 | November 23, 2026 | $375,000 | Same assistance listing 93.853 as 2 awards here |
| Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional) | PA-23-317 | NIH | 93.394 | November 24, 2026 | Not listed | Same assistance listing 93.394 as 2 awards here |
| Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) | RFA-OD-27-008 | NIH | 93.853 | December 2, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.853 | December 3, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.853 | December 3, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.853 | December 4, 2026 | Not listed | Same assistance listing 93.853 as 2 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.853 | January 7, 2027 | $375,000 | Same assistance listing 93.853 as 2 awards here |
| Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) | PAR-25-079 | NIH | 93.394 | January 7, 2027 | $500,000 | Same assistance listing 93.394 as 2 awards here |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | PAR-25-081 | NIH | 93.394 | January 7, 2027 | $499,999 | Same assistance listing 93.394 as 2 awards here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.